About this trial
Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Older than 18 years old
Elective surgery
ASA 1, 2, 3
At least one risk factor for PONV
Disqualifiers
Pregnancy
Receiving antiemetics prior to arrival to preoperative holding area
Receiving opioids prior to arrival to preoperative holding area
Admission to ICU
Trial population
Adult surgical patients scheduled for elective surgery
Trial design
Case-control
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Rate of PONV
Number of events of PONV during 2 hours after admission to PACU
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: